DeepMed Research

HACKENSACK MERIDIAN HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2016-01-01

Employees: -

Market Cap: -

Website: https://www.hackensackmeridianhealth.org/

Clinical Trials

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

First Posted Date: 2012-11-08

Last Posted Date: 2022-10-10

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 21

Registration Number: NCT01723839

Locations: 🇺🇸
John Theurer Cancer Center at HackensackUMC, Hackensack, New Jersey, United States

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Vorinostat, Lenalinomide and Dexamethasone

First Posted Date: 2011-12-30

Last Posted Date: 2022-01-21

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 25

Registration Number: NCT01502085

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Blood Conservation in Cardiac Surgery

Not Applicable

Withdrawn

Conditions: Transfusion Reactions
Post Cardiac Surgery

Interventions: Other: Blood transfusion

First Posted Date: 2011-11-01

Last Posted Date: 2018-07-24

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT01463345

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

PRO#0118: Decitabine Plus Mini Flu-Bu

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine plus Fludarabine and Busulfan

First Posted Date: 2011-10-20

Last Posted Date: 2014-02-04

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 20

Registration Number: NCT01455506

Locations: 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Phase 1

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: Cyclophosphamide and Sirolimus
Drug: Low dose IL-2 with Cytoxan + Sirolimus
Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Drug: Low dose IL-2, Vidaza, Cytoxan & Sirolimus

First Posted Date: 2011-10-17

Last Posted Date: 2022-03-02

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 3

Registration Number: NCT01453140

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Bortezomib

First Posted Date: 2011-10-17

Last Posted Date: 2023-11-28

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 63

Registration Number: NCT01453088

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Fludarabine monophosphate, melphalan, Bortezomib

First Posted Date: 2011-10-17

Last Posted Date: 2022-05-25

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 54

Registration Number: NCT01453101

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Phase 3

Terminated

Conditions: Myeloid Malignancies
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Myeloproliferative Disorders
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)

First Posted Date: 2011-06-06

Last Posted Date: 2023-06-13

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 53

Registration Number: NCT01366612

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone

First Posted Date: 2011-02-17

Last Posted Date: 2024-12-16

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 17

Registration Number: NCT01297764

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Revlimid

First Posted Date: 2010-11-16

Last Posted Date: 2023-09-14

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 18

Registration Number: NCT01241734

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy